AstraZeneca PLC (LON:AZN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
12,406
-140 (-1.12%)
Oct 28, 2025, 4:36 PM BST
-1.12%
Market Cap192.38B
Revenue (ttm)41.24B
Net Income (ttm)6.05B
Shares Out1.55B
EPS (ttm)3.87
PE Ratio32.02
Forward PE16.83
Dividend2.40 (1.91%)
Ex-Dividend DateAug 7, 2025
Volume1,482,319
Average Volume2,305,622
Open12,586
Previous Close12,546
Day's Range12,406 - 12,708
52-Week Range9,574 - 12,972
Beta0.16
RSI53.31
Earnings DateNov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange London Stock Exchange
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

AstraZeneca breached the UK pharmaceutical industry's code of practice by using a claim that misleadingly implied its Symbicort asthma drug was suitable for all newly diagnosed patients aged 12 years ...

4 days ago - Reuters

Peering Into AstraZeneca PLC's Recent Short Interest

AstraZeneca PLC's (NYSE: AZN) short interest as a percent of float has fallen 28.0% since its last report. According to exchange reported data, there are now 5.46 million shares sold short , which is...

6 days ago - Benzinga

Novavax (NVAX) Sells Facility to AstraZeneca for $60M in Strategic Deal

Novavax (NVAX) Sells Facility to AstraZeneca for $60M in Strategic Deal

6 days ago - GuruFocus

AstraZeneca's Tezspire Receives EU Approval for Severe Rhinosinusitis

AstraZeneca's Tezspire Receives EU Approval for Severe Rhinosinusitis

6 days ago - GuruFocus

AstraZeneca Bolsters Oncology with £1.2 Billion Fusion Buyout Amid UK Growth

As part of its move to strengthen its oncology leadership, AstraZeneca has declared the purchase of Fusion Pharmaceuticals at PS1.2 billion, which focuses on novel radioconjugate therapies, as demand ...

6 days ago - ABC Money

AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps

(RTTNews) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for adult patients with s...

7 days ago - Nasdaq

AstraZeneca PLC (AZN) Presents at ESMO Congress 2025 - Slideshow

2025-10-21. The following slide deck was published by AstraZeneca PLC in conjunction with this event.

7 days ago - Seeking Alpha

The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies

Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.

7 days ago - Nasdaq

Trump’s pharma strategy ‘holds Europe hostage’, Finnish MEP warns

Trump’s deals with Pfizer, AstraZeneca, and Merck expose risk to EU

8 days ago - EURACTIV.com

Top Research Reports for AstraZeneca, RTX & Applied Materials

AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.

8 days ago - Nasdaq

AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure

AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure

8 days ago - GuruFocus

AstraZeneca hails major breakthroughs with breast-cancer drugs

An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 billion worth of company sales in five years’ time.

8 days ago - MarketWatch

AstraZeneca: CHMP Recommends Saphnelo For Approval

(RTTNews) - AstraZeneca (AZN) said its Saphnelo or anifrolumab has been recommended for approval in the European Union as a self-administered once-weekly pre-filled pen for adult patients with systemi...

9 days ago - Nasdaq

AstraZeneca (AZN) Reports Positive Phase III Trial Results for Datroway

AstraZeneca (AZN) Reports Positive Phase III Trial Results for Datroway

9 days ago - GuruFocus

AstraZeneca (AZN) Reports Success in Breast Cancer Trial with Enhertu

AstraZeneca (AZN) Reports Success in Breast Cancer Trial with Enhertu

9 days ago - GuruFocus

AstraZeneca (AZN) Reports Promising Results in Breast Cancer Trial

AstraZeneca (AZN) Reports Promising Results in Breast Cancer Trial

9 days ago - GuruFocus

Significant Trial Results Boost AstraZeneca's ENHERTU in Breast Cancer Treatment

Significant Trial Results Boost AstraZeneca's ENHERTU in Breast Cancer Treatment

9 days ago - GuruFocus

AZN: Promising Results from DESTINY-Breast11 Phase III Study

AZN: Promising Results from DESTINY-Breast11 Phase III Study

9 days ago - GuruFocus

Top global stories this week: AstraZeneca, Taiwan Semiconductor Manufacturing among notable names

US stock indexes ended the week higher, supported by encouraging earnings reports from major U.S. banks.

9 days ago - Seeking Alpha

AstraZeneca's Datroway extends survival in aggressive breast cancer

AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat for...

10 days ago - Reuters

AstraZeneca : ENHERTU Shows Significant Survival Benefit In DESTINY-Breast05 Phase III Trial

(RTTNews) - AstraZeneca announced that the Phase III DESTINY-Breast05 trial demonstrated ENHERTU (fam-trastuzumab deruxtecan-nxki) significantly improves invasive disease-free survival (IDFS) in patie...

10 days ago - Nasdaq

AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials

AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials

10 days ago - GuruFocus

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.

10 days ago - Reuters

AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash

AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO.

10 days ago - Investor's Business Daily